Obesity is a serious and widespread health problem which has become a growing concern in many societies. Most currently available weight-loss medications do not work for everyone, and the effects decline over time. Thus, there is an urgent need to identify new molecular targets to improve drug development for the treatment of obesity and obesity-related diseases. In this study, we discovered that the histone deacetylase 11 (HDAC11) enzyme is a key regulator of metabolism and obesity, and the absence of HDAC11 prevents obesity in mice. Our findings will facilitate the development of novel therapeutics to treat obesity by targeting HDAC11.
Introduction
Histone deacetylases (HDACs) regulate a wide range of biological functions by removing acetyl and acyl groups from lysine residues on histones and non-histone proteins. There are two categories of HDACs, the Zn 2+ -dependent deacetylases (HDAC1-11) and the NAD + -dependent deacetylases (SIRT1-7). Based on sequence similarities, eighteen HDACs have been grouped into four classes (1) . Class I HDACs (HDAC1, 2, 3 and 8) are similar to Saccharomyces cerevisiae RPD3. Class II (HDAC4, 5, 6, 7, 9, and 10) share a similar core sequence with yeast HDA1. SIRT1-7 belong to Class III, which are orthologs of yeast SIR2 (silent information regulator 2). HDAC11 is the sole Class IV HDAC, which shares its highly conserved critical residues in the catalytic core regions with both class I and II HDACs.
Many studies have established that abnormal HDACs play a key role in human diseases including cancer, neurological diseases, metabolic/endocrine disorders, inflammatory diseases, immunological disorders, cardiovascular diseases, and pulmonary diseases. As a result, there is significant interest in targeting HDACs for therapeutic purposes. In the area of metabolic/endocrine disorders, there is increasing evidence that Class I, II and III HDACs are intimately involved in the regulation of metabolism, and dysregulation of these HDACs may lead to maladies such as obesity and type 2 diabetes.
For Class I HDACs, overexpression of HDAC1 blocks, whereas deleting HDAC1 significantly enhances, b-adrenergic activation-induced BAT-specific gene expression in brown adipocytes, suggesting that targeting HDAC1 may be beneficial in the prevention and treatment of obesity by enhancing BAT thermogenesis. (2) . It has been reported that hepatic deletion of HDAC3 leads to lipid accumulation in the liver (3) and disrupts normal metabolic homeostasis (4) . HDAC3 inhibition, however, improves glycemia and insulin secretion in obese diabetic rats (5) . Treatment of mice with MS-275, an HDAC1/HDAC3 inhibitor, stimulates the functionality and oxidative potential of adipose tissue, improves glucose tolerance and ameliorates the 5 metabolic profile in diet-induced obese mice (6) . In a contrasting study, inhibition of HDAC8 causes insulin resistance (7) .
For Class II HDACs, high HDAC5 and HDAC6 expression levels are required for adequate adipocyte function (8) . HDAC9 gene deletion prevents the detrimental effects of chronic high-fat feeding on adipogenic differentiation, increases adiponectin expression, and enhances energy expenditure by promoting beige adipogenesis, thus leading to reduced body mass and improved metabolic homeostasis (9) .
Sirtuins, the Class III histone deacetylase family, are regulators of metabolism, and like Class I and II HDACs, may also be therapeutic intervention targets. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation (10) .
Ablation of SIRT6 in mice results in severe hypoglycemia, as well as liver steatosis (11) .
Additionally, while neural-specific deletion of SIRT6 in mice promoted diet-induced obesity and insulin resistance (12) , SIRT6 overexpression protected against these effects (13) .
Unlike Class I, II, and III HDACs, there is limited information on the role of HDAC11, the sole Class IV HDAC, in the regulation of metabolic pathways and almost nothing is known about its potential role in obesity. In fact, most studies on HDAC11 have focused on its function in immune and neuro systems, as well as in cancer development. In addition to its potential modest deacetylase activity, recent studies suggest that HDAC11 is a long chain fatty-acid deacylase (14) . Similar to posttranslational lysine acetylation/deacetylation, protein acylation/deacylation is a mechanism of biological signaling and many fatty acylated proteins play key roles in regulating cellular structure and function. Therefore, we sought to determine if HDAC11 may also impact metabolic phenotypes and core metabolic pathways.
Here we report a novel key regulatory function of HDAC11 in metabolic homeostasis.
HDAC11 deletion protected mice from high-fat diet (HFD)-induced obesity, insulin resistance and hepatic steatosis. These results uncovered the potential prospect of HDAC11 inhibitors in therapy of obesity and obesity-related diseases.
Results

HDAC11 knockout mice display resistance to HFD-induced obesity
To study the function of HDAC11 in metabolic homeostasis, we first assessed if the loss of HDAC11 had any effect on animal body weight maintained under HFD. HDAC11 knockout (KO) mice were generated with a targeted deletion of floxed exon 3 of Hdac11, and the KO was confirmed by genotyping mouse-tail DNA derived from wild-type (WT) and HDAC11 KO mice (Figs. S1A, B) . Loss of HDAC11 protein expression was also verified by Western blot analysis of protein extracts from WT and HDAC11 KO mouse brains (Fig. S1C ).
When male WT and HDAC11 KO mice were fed HFD (42% kcal from fat; ad libitum from 3-week-old), a significant difference in body weight between the two groups was observed beginning at about 10 weeks (Fig. 1A) . Maintaining the animals on HFD for up to 30 weeks resulted in approximately 25% more body weight gain in WT mice compared to HDAC11 KO mice (Fig. 1B) . Furthermore, the epididymal white adipose tissue (eWAT) weight was significantly reduced in HDAC11 KO mice compared to WT after 20 weeks feeding on HFD ( To investigate whether energy intake plays a role in HDAC11 KO-driven obesity resistance, we compared the amount of food consumption between the two groups using a comprehensive cage monitoring system for 96 hours. We found no statistical differences in food consumption between WT and HDAC11 KO mice (Fig. 1F ). Further comparison of food intake for 17 consecutive weeks, showed that no marked difference was observed between WT and HDAC11 KO mice (Fig. S2) . In contrast to food intake, water consumption was significantly increased in WT animals, and the higher water intake by WT mice occurred across both light phase and dark phase, suggesting a status of polydipsia (Fig. 1G ).
HDAC11 knockout mice are protected from HFD-associated hypercholesterolemia and hyperinsulinemia
To determine if HDAC11 affects hyperlipidemia under HFD, we tested cholesterol and triglyceride (TG) levels in plasma of WT and HDAC11 KO mice. HFD feeding for 20 weeks increased cholesterol level in WT mice, but not in HDAC11 KO mice ( Fig. 2A) . For plasma TG, there was a slight, but not significant, difference between HDAC11 KO and WT groups after 20-week of HFD (Fig. 2B) , which is consistent with a previous report of decreased circulating TG levels in HFD fed C57BL/6 mice (15). We further measured liver TG level, which was markedly reduced in HFD-fed HDAC11 KO mice compared to WT mice (Fig. 2C ).
Because HDAC11 deficient mice have less excessive drinking behavior compared to WT mice, we measured both fasting and non-fasting blood glucose levels to assess the diabetes status in these animals. The results show that there is no marked difference between HDAC11 KO and WT mice (Fig. 2D ). To further explore the role of HDAC11 in glucose metabolism, blood insulin levels were measured, which showed a significant decrease in HDAC11 KO mice (Fig.   2E ). Also, compared to WT animals, HDAC11 KO mice show improved glucose tolerance as determined by the glucose tolerance test (GTT), which measures the clearance by the body of an injected glucose load (Fig. 2F) . Similarly, using the insulin tolerance test (ITT), which monitors endogenous glucose disappearance over time in response to an insulin injection, HDAC11 KO mice have a significant greater reduction in blood glucose levels after insulin challenge compared to WT mice (Fig. 2G ). Together these findings suggest that HDAC11 plays an important role in maintaining glucose homeostasis and insulin sensitivity. The effect of HDAC11 in HFD-associated hyperinsulinemia are not due to changes in the mRNA expression levels of insulin or glucagon receptors (Fig. S3 ). There is also no difference in the animals' hematology examination results (Table S1 ). Histological examination revealed severe steatosis and lipid accumulation in WT, but not in HDAC11 KO, mouse livers (Fig. 3C) . Oil red O stain also showed extensive accumulation of large lipid droplets in the liver of WT, but not HDAC11 KO mice (Fig. 3D) . These results are consistent with our observation that the liver TG level was significantly reduced in HFD-fed HDAC11 KO mice ( 
HDAC11 deficiency enhances thermogenic potential and promotes UCP1 expression
Total energy expenditure in mammals is a sum of energy utilization during external physical activity and internal heat production. After monitoring locomotor activity with the Phenomaster System for four consecutive days, the total locomotor activity in the XYZ plane, horizontal activity in the XY plane, and rearing activity in the Z plane of WT and HDAC11 KO mice, were compared and showed no statistical differences (Fig S5A-H) . These results argue that the resistance of HDAC11 KO mice to HFD-induced obesity depends more on metabolic mechanisms than on physical activity.
Defect in non-shivering thermogenesis appears to be constitutive, rather than a secondary consequence of obesity (16) . We found that body temperature was significantly increased in both normal (ND)-and HFD-fed HDAC11 KO mice compared to WT mice at room temperature ( Fig. 4A) . By performing the cold challenge experiment (4°C for 6-hour), in stark contrast to WT mice, HDAC11 KO mice under either ND or HFD exhibited a marked increase in thermogenesis and effective resistance to a drop in body temperature (Fig. 4B ).
Brown adipose tissue (BAT) is specialized in adaptive thermogenesis through heat production in response to cold or excess calories. It was unequivocally demonstrated that the majority of human adults possess active BAT, which is associated with a favorable metabolic phenotype (17) . As shown in 
HDAC11 deficiency promotes oxygen consumption and elevates CPT1 activity
Oxygen consumption has been used as the golden standard for indirect calorimetry. To further understand the resistance to HFD-induced obesity in HDAC11 KO mice, we measured oxygen consumption (VO2), carbon dioxide production (VCO2) and respiratory exchange ratio (RER; VCO2/VO2). As shown in Figs. 5A, B, the 24-hour oxygen consumption and carbon dioxide production of HDAC11 KO mice are significantly elevated across both light and dark phases. As expected, there was no difference in RER level between WT and HDAC11 KO mice. However, an increased RER of HDAC11 KO mice in the dark phase was statistically significant, when compared to that in the light phase (Fig. 5C ), suggesting that HDAC11 KO reversed the HFDinduced disruption of circadian rhythms. The energy expenditure could also be assessed through the metabolic rate, which is calculated with the parameters of VO2, VCO2 and body weight. As shown in Fig. 5D , deletion of HDAC11 resulted in a significant elevation of total calories expenditure across light and dark phases, highlighting the importance of enhanced metabolic activity in HDAC11 KO mice for resistant to obesity.
Given our observation that the absence of HDAC11 promoted oxygen consumption and metabolic activity, we hypothesize that fat oxidation serves as a crucial mechanism for energy expenditure. Carnitine palmitoyltransferase 1 (CPT1), which initiates the first step of the oxidative pathway in the mitochondrial matrix, is the key regulatory enzyme of mitochondrial long-chain fatty acid β-oxidation (20) . As shown in Fig. 5E , liver CPT1 activity is markedly elevated in HDAC11 KO mice.
To further verify the impact of HDAC11 deficiency on mitochondrial respiration, we measured the mitochondrial oxygen consumption rate (OCR) under basal and stress conditions in AML12 cells. In comparison to control cells, HDAC11 KD cells showed an increased OCR even under basal conditions (Fig. 5F ). HDAC11 KD also significantly elevated maximal respiration driven by a mitochondrial uncoupling agent, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP). Moreover, the spare respiratory capacity (difference between maximal and basal respiration) was markedly elevated in HDAC11 KD cells, suggesting that a decrease in HDAC11 enhances the ability to respond to an increased energy demand under stress conditions (21) .
HDAC11 deficiency elevates plasma adiponectin and activates the adipoR-AMPK signaling pathway in the liver
Adiponectin, the most abundant adipose-specific adipokine, is a hormone involved in regulating glucose levels and fatty acid degradation. An association between reduced adiponectin production and the pathogenesis of non-alcoholic fatty liver disease (NAFLD) has been confirmed in numerous studies (22, 23) . Results from our ELISA analysis revealed significantly elevated plasma adiponectin levels in 20-week HFD-fed HDAC11 KO mice (Fig. 6A) . The
AdipoQ gene mRNA expressions in the eWAT, BAT, and liver of HDAC11 KO mice were also markedly increased compared to the WT animals (Fig. 6B ).
Adiponectin signaling is mainly mediated through the AdipoR1-AMP-activated protein kinase (AMPK) and AdipoR2-peroxisome proliferator-activated receptor α (PPARα) pathways in the liver (24) . Consistent with previous reports that AdipoR2 mRNA levels reduced in NAFLD patients and hepatocytes induced by fatty acid (25) , RT-qPCR analysis confirmed an increase in adiponectin receptor 2 (AdipoR2), but not adiponectin receptor 1 (AdipoR1), in the livers of HDAC11 KO mice (Fig. S6) .
AMPK signaling plays an essential role in adiponectin-mediated beneficial effects on adipose tissue and lipid metabolism. One of the most well-defined mechanisms of AMPK activation is phosphorylation at Thr172 of the α-subunit (26) . As shown in Fig. 6C , compared to WT animals, Thr172 of AMPK is hyperphosphorylated in hepatic tissues from HDAC11 KO mice. Additionally, phosphorylation at Ser79 of acetyl-CoA carboxylase (ACC), a downstream substrate of AMPK (27) , was increased in parallel with AMPK activity (Fig. 6C ). These results demonstrate that HDAC11 deletion increases AMPK activity and stimulates the AMPK-ACC signaling pathway.
Previous studies using AdipoR1 KO mice showed that the loss of AdipoR1 increased adiposity associated with decreased glucose tolerance and energy expenditure. However, AdipoR2 KO mice were lean and resistant to HFD-induced obesity associated with improved glucose tolerance, higher energy expenditure, and reduced plasma cholesterol levels (28) . To further study the effect of HDAC11 and adiponectin, we activated AdipoR with AdipoRon, an adiponectin receptor agonist that binds both AdipoR1 and AdipoR2 (29) , in AML12 cells.
AdipoRon activated the phosphorylation of Thr172-AMPK and Ser79-ACC in a dose-dependent manner in both control and HDAC11 KD AML12 cells (Fig. S7A) . Oral administration of HFD-fed mice with AdipoRon (50mg kg -1 body weight/day) for 10 days revealed no further increase of phospho-AMPK and phospho-ACC in the liver of HDAC11 KO mice, suggesting a maximized signaling stimulation by AdipoRon. (Fig. S7B) . Indeed, AdipoRon treatment effectively prevents an increase in liver TG in HFD-fed WT mice, and because the receptor agonist did not further inhibit liver TG levels in HDAC11 KO mice, it is reasonable to conclude that HDAC11 deficiencyactivated adiponectin-AdipoR-AMPK pathway serves as a major mechanism in the attenuation of hepatic TG accumulation (Fig. 6D ).
In summary, our results convincingly show that HDAC11 is an important metabolic regulator. Mice that lack HDAC11 are protected from diet-induced obesity and fatty liver.
HDAC11 deletion inhibited HFD associated hypercholesterolemia, hyperinsulinemia and reversed liver injury. HDAC11 deficiency boosted thermogenesis, which is associated with increased UCP1 expression in BAT. The loss of HDAC11 elevated CPT1 activity and mitochondrial oxygen consumption, a key pathway for energy expenditure. A significant increase in adiponectin production by HDAC11 deletion might serve as another important regulatory mechanism that activates adiponectin-associated signaling and re-programming (Fig.   6E ).
Discussion
In this study, we show that the absence of HDAC11 prevented obesity and ameliorated pathological manifestations associated with chronic high-fat feeding in mice, including glucose intolerance, insulin resistance, hypercholesterolemia, and hepatosteatosis. Under HFD, compared to WT animals, HDAC11 KO mice were healthy and showed no apparent abnormality in their appearances or behaviors throughout our studies.
Accumulating evidence indicates a link between metabolic disorders and dysregulated Our results are consistent with a recent report that HDAC11 is a fatty-acid deacylase rather than deacetylase, and this function of HDAC11 is phylogenetically conserved (14) . Identification of HDAC11 de-fatty-acylation targets will help to further understand how the lack of HDAC11 prevents obesity in animals as well as the roles and functions of HDAC11-mediated metabolic reprogramming.
14 BAT is a regulator of energy expenditure and body fat in humans and rodents. We found an increase in thermogenesis in HDAC11 KO mice accompanied with high expression of UCP1, which is responsible for uncoupling and proton leak across the inner mitochondrial membrane and heat production. Increased BAT capacity of thermogenesis relies on the expression of preventing excess TG storage in the liver (26, 40) . We have provided evidence that HDAC11 impacts plasma adiponectin levels, adiponectin-AMPK activation, and adiponectin-AMPK signaling-mediated metabolism outcomes, such as hepatic TG accumulation.
In conclusion, our study reveals a novel physiological function for HDAC11, which regulates metabolism homeostasis through boosting UCP1 expression, promoting CPT1 enzyme activity, elevating plasma adiponectin, and activating adiponectin-AdipoR-AMPK pathway. These findings warrant further investigations into targeting HDAC11 for obesity and related metabolic diseases.
Methods
Animals. WT and HDAC11 KO mice are on C57BL/6 background. To assess metabolic parameters, male HDAC11 KO and WT mice at 3 weeks of age were fed a HFD (Adjusted Calories Diet, TD. 88137, Harlan, 42% kcal from fat, 42.7% kcal from carbohydrate, and 15.2%
kcal from protein) for the indicated times. Mice body temperature recordings were determined with YSI 4600 Precision thermometer (YSI, Inc., Yellow Springs, OH).
Comprehensive Cage Monitoring System. Comprehensive metabolic cages were used to identify altered physiological systems in response to HFD. Phenomaster System (TSE Systems, USA) accommodating 12 mice simultaneously was used to measure calorimetry, activity, circadian patterns, water and food intake for 7 consecutive days. The equipment measured the volumes of O2 consumed and CO2 produced in air samples independently from each cage, calculating respiratory exchange ratio, and metabolic rate corrected for body weight. Food and water intake were measured directly and corrected for spillage. Locomotor activity was measured every 10 seconds by counting the number of infrared beam breaks in the X, Y, and Z planes. After a 3-day habituation period to the metabolic cages, 96 h of data was analyzed, with the reviewer blind to the genotype, for all measurements.
Cell culture. Mouse normal hepatocyte AML12 was purchased from American Type Culture
Collection. Cells were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 5 ng/ml selenium and 40ng/ml dexamethasone with 10% fetal bovine serum (FBS), at 37ºC in a humidified atmosphere of 5%
CO2.
Antibodies and reagents. AMPKα (2532), phosphor-AMPKα (T172) (2531), ACC (3662) and phosphor-ACC (S79) (11818) antibodies were purchased from Cell Signaling Technology. Immunoblotting. Cells were lysed in NETN buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and protease inhibitor cocktail) with 2 mM sodium orthovanadate, 2 mM sodium fluoride, 50mM nicotinamide and 25 mM β-glycerophosphate. Fresh mice tissues were quickly frozen with liquid nitrogen, and homogenized in NETN buffer with 2 mM sodium orthovanadate, 2 mM sodium fluoride, 50mM nicotinamide and 25 mM β-glycerophosphate in a Potter-Elvehjem homogenizer followed by ultrasonication on ice. Samples were centrifuged for 10 min at 12,000g at 4ºC, and protein contents of the samples were determined by the Bradford assay. Proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, MA), which was probed with primary and secondary antibodies.
Proteins were visualized using a chemiluminescence detection kit (Pierce). RT-qPCR. Total RNA was isolated from mouse tissues using the mirVana isolation kit (Applied Biosystems). Total RNAs from at least three mice were mixed equally. Reverse transcription was carried out by the qScript cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD).
Relative quantitation of mRNAs was tested via SYBR green-based quantitative PCR and specific primers (Table S2) . qPCR was carried out by 7900 HT fast real-time PCR system (Applied Biosystems) following the manufacturer's instruction of iQ SYBR green Supermix (BioRad). Mice GAPDH served as an internal control, and PCR results were analyzed using the 2 -(ΔΔCT) method.
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Statistical analysis. Statistical differences were detected using t-tests when only comparing two groups or ANOVA plus post-hoc comparison for multiple comparisons with significance set at p<0.05, and very significance set at p<0.01. (GraphPad Prism 7.03). 
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